Skip to main content

Table 1 Association between DNMT1 promoter methylation and clinicopathological features in BRCA1-mutated breast cancer

From: Regulation of DNA methyltransferase 1 transcription in BRCA1-mutated breast cancer: a novel crosstalk between E2F1 motif hypermethylation and loss of histone H3 lysine 9 acetylation

  n M (%) UM (%) P
Age at diagnosis       1.000
≤ 50 y 30 14 35.90 16 34.78  
> 50 y 55 25 64.10 30 65.22  
Menstrual status       0.282
Premenopausal 38 20 51.28 18 39.13  
Postmenopausal 47 19 48.72 28 60.87  
Tumor size       0.164
≤ 5 cm 59 24 61.54 35 76.09  
> 5 cm 26 15 38.46 11 23.91  
Histological grade       0.006
I-II 63 23 58.97 40 86.96  
III 22 16 41.03 6 13.04  
LN status       0.014
Positive 35 22 56.41 13 28.26  
Negative 50 17 43.59 33 71.74  
ER status       0.282
Positive 47 19 48.72 28 60.87  
Negative 38 20 51.28 18 39.13  
PR status       0.269
Positive 50 20 51.28 30 65.22  
Negative 35 19 48.72 16 34.78  
c-erbB-2 status       0.378
Positive 36 19 48.72 17 36.96  
Negative 49 20 51.28 29 63.04  
p53 status       0.258
Positive 30 11 28.21 19 41.30  
Negative 55 28 71.79 27 58.70  
Ki67 status       0.030
Positive 62 33 84.62 29 63.04  
Negative 23 6 15.38 17 36.96  
E-cadherin status       0.030
Positive 68 27 69.23 41 89.13  
Negative 17 12 30.77 5 10.87  
  1. M, methylated; UM, unmethylated; LN, lymph node; ER, estrogen receptor; PR, progesterone receptor.